

# Dipak Kotecha, Fesc

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626707/publications.pdf>

Version: 2024-02-01

107  
papers

31,698  
citations

61857

43  
h-index

32761

100  
g-index

116  
all docs

116  
docs citations

116  
times ranked

21620  
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
2	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
3	A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.	2.9	14
4	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
5	Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 1600-1607.	1.2	15
6	Identification and Mapping Real-World Data Sources for Heart Failure, Acute Coronary Syndrome, and Atrial Fibrillation. <i>Cardiology</i> , 2022, 147, 98-106.	0.6	9
7	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
8	Cardiac Imaging to Assess Left Ventricular Systolic Function in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 139, 40-49.	0.7	5
9	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
10	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	1.0	4
11	Transforming clinical research by involving and empowering patients—the RATE-AF randomized trial. <i>European Heart Journal</i> , 2021, 42, 2411-2414.	1.0	8
12	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 902-908.	1.2	7
13	Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. <i>BMC Medicine</i> , 2021, 19, 85.	2.3	33
14	Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1681.	3.8	1
15	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003599.	3.9	16
16	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
17	Redefining $\beta$ -blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. <i>Lancet, The</i> , 2021, 398, 1427-1435.	6.3	52
18	Quality and Completeness of Myocardial Infarction Recording in Clinical Practice Research Datalink Aurum. <i>Clinical Epidemiology</i> , 2021, Volume 13, 745-753.	1.5	14

#	ARTICLE	IF	CITATIONS
19	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
20	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
21	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
22	Response to the Letter from Dr. Wei Hui, Regarding the Recent Publication of "A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements". <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1293.	1.2	1
23	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020, 41, 3605-3692.	1.0	38
24	Importance and Assessment of Quality of Life in Symptomatic Permanent Atrial Fibrillation: Patient Focus Groups from the RATE-AF Trial. <i>Cardiology</i> , 2020, 145, 666-675.	0.6	9
25	Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. <i>BMC Medicine</i> , 2020, 18, 103.	2.3	40
26	STEEER-AF: a cluster-randomized education trial from the ESC. <i>European Heart Journal</i> , 2020, 41, 1952-1954.	1.0	9
27	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. <i>Europace</i> , 2020, 22, 748-760.	0.7	72
28	Longitudinal Assessment of Cardiac Involvement in Fabry Disease Using Cardiovascular Magnetic Resonance Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1850-1852.	2.3	5
29	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2497.	3.8	118
30	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. <i>Europace</i> , 2019, 21, 1776-1784.	0.7	22
31	A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1505-1515.	1.2	98
32	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. <i>Systematic Reviews</i> , 2019, 8, 221.	2.5	2
33	Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?. <i>European Journal of Heart Failure</i> , 2019, 21, 480-481.	2.9	0
34	Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?. <i>European Heart Journal</i> , 2019, 41, 652-654a.	1.0	9
35	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RailRoAD) compared with current standard practice. <i>Trials</i> , 2019, 20, 314.	0.7	6
36	Education as a vehicle towards quality improvement in the European Society of Cardiology. <i>Cardiovascular Research</i> , 2019, 115, e80-e81.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	0.8	50
38	B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. <i>BMC Medicine</i> , 2019, 17, 72.	2.3	14
39	Digital learning and the future cardiologist. <i>European Heart Journal</i> , 2019, 40, 499-501.	1.0	14
40	Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. <i>Europace</i> , 2019, 21, 746-753.	0.7	39
41	10â€¦A simple method to improve the reliability of echocardiography in patients with atrial fibrillation. , 2019, , .		0
42	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. <i>Heart</i> , 2019, 105, 1825-1831.	1.2	15
43	Impact of Renal Impairment on Beta-Blocker Efficacy in Patientsâ€Withâ€Heartâ€Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	1.2	39
44	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.5	6
45	Effects of blood pressure-lowering drugs in heart failure. <i>Journal of Hypertension</i> , 2019, 37, 1757-1767.	0.3	7
46	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019, 40, 1728-1738.	1.0	8
47	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1268-1276.	1.0	96
48	The future of continuing medical education: the roles of medical professional societies and the health care industry. <i>European Heart Journal</i> , 2019, 40, 1720-1727.	1.0	11
49	Incidence and clinical implications of intraoperative bilateral internal thoracic artery graft conversion: Insights from the Arterial Revascularization Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2346-2355.e6.	0.4	28
50	Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial). <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	10
51	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. <i>European Heart Journal</i> , 2018, 39, 1481-1495.	1.0	163
52	Totally thoracoscopic ablation for atrial fibrillation: a systematic safety analysis. <i>Europace</i> , 2018, 20, 1790-1797.	0.7	45
53	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. <i>Europace</i> , 2018, 20, 225-233.	0.7	97
54	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 105.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
56	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38
57	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	1.0	426
58	Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. <i>Europace</i> , 2018, 20, f153-f161.	0.7	80
59	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1984-1986.	1.2	18
60	Thoracoscopic Left Atrial Appendage Clipping. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 893-901.	1.3	42
61	Co-morbidity (HF <sub>r</sub> EF and HF <sub>p</sub> EF): atrial fibrillation. , 2018, , 1797-1801.		2
62	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	1.2	104
63	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	187
64	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.	1.2	198
65	Observational Versus Randomized. <i>JACC: Heart Failure</i> , 2017, 5, 395-396.	1.9	0
66	Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. <i>Europace</i> , 2017, 19, 1427-1438.	0.7	48
67	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 50.	0.4	280
68	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2017, 22, 731-741.	1.7	98
69	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	0.8	37
70	ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017, 38, 2643-2645.	1.0	9
71	Neurohormonal Blockade in Heart Failure. <i>Cardiac Failure Review</i> , 2017, 03, 19.	1.2	53
72	2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH EACTS. <i>Russian Journal of Cardiology</i> , 2017, , 7-86.	0.4	87

#	ARTICLE	IF	CITATIONS
73	Digoxin: The good and the bad. Trends in Cardiovascular Medicine, 2016, 26, 585-595.	2.3	102
74	Letter: Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients – Response. International Journal of Cardiology, 2016, 214, 516-517.	0.8	0
75	Magnesium for Atrial Fibrillation, Myth or Magic?. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	12
76	Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	86
77	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
78	Authors’ reply to Cunningham and Messerli and colleagues. BMJ, The, 2016, 353, i3141.	3.0	0
79	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
80	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
81	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	1.2	292
82	What’s new in the 2016 ESC Guidelines on atrial fibrillation?. European Heart Journal, 2016, 37, 2851-2852.	1.0	2
83	In memoriam Henry Krum, 1958-2015. Cardiology, 2016, 134, 107-108.	0.6	34
84	Effect of age and sex on efficacy and tolerability of $\beta$ blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.	3.0	95
85	Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.	1.3	37
86	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. International Journal of Cardiology, 2016, 203, 660-666.	0.8	161
87	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
88	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. PLoS ONE, 2016, 11, e0165790.	1.1	44
89	Qualifying the Use of Common Cardiovascular Drugs in Cardiology. Circulation Journal, 2015, 79, 517-518.	0.7	1
90	Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. Stroke, 2015, 46, 608-609.	1.0	11

#	ARTICLE	IF	CITATIONS
91	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2523-2528.	1.0	57
92	26â€...Digoxin â€“ Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. <i>Heart</i> , 2015, 101, A14.2-A15.	1.2	1
93	Î² blockers in patients with heart failure and atrial fibrillation â€“ Authors' reply. <i>Lancet, The</i> , 2015, 385, 1618-1619.	6.3	4
94	Atrial fibrillation in heart failure: what should we do?. <i>European Heart Journal</i> , 2015, 36, ehv513.	1.0	243
95	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015, 351, h4451.	3.0	247
96	Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. <i>Evidence-Based Medicine</i> , 2014, 19, 222-223.	0.6	17
97	Efficacy of Î² blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. <i>Lancet, The</i> , 2014, 384, 2235-2243.	6.3	475
98	Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. <i>Systematic Reviews</i> , 2013, 2, 7.	2.5	21
99	Radial artery pulse wave analysis for non-invasive assessment of coronary artery disease. <i>International Journal of Cardiology</i> , 2013, 167, 917-924.	0.8	11
100	Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm. <i>Hypertension Research</i> , 2013, 36, 854-855.	1.5	2
101	Five-minute heart rate variability can predict obstructive angiographic coronary disease. <i>Heart</i> , 2012, 98, 395-401.	1.2	50
102	Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. <i>American Heart Journal</i> , 2011, 161, 822-831.e2.	1.2	67
103	Contemporary predictors of coronary artery disease in patients referred for angiography. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 280-288.	3.1	11
104	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. <i>The Cochrane Library</i> , 2010, , CD007613.	1.5	50
105	Thienopyridines in Stable Coronary Disease. , 2010, , 131-141.		0
106	Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. <i>European Journal of Heart Failure</i> , 2009, 11, 872-880.	2.9	85
107	Improved Risk Prediction Using Non-Invasive Methodsâ€”The Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study. <i>Heart Lung and Circulation</i> , 2008, 17, S72.	0.2	0